Literature DB >> 16513527

Factor VIII structure and function.

Philip J Fay1.   

Abstract

Factor VIII, a non-covalent heterodimer comprised of a heavy chain (A1-A2-B domains) and light chain (A3-C1-C2 domains), circulates as an inactive procofactor in complex with von Willebrand factor. Metal ions are critical to the integrity of factor VIII, with Cu and Ca ions stabilizing the heterodimer and generating the active conformation, respectively. Activation of factor VIII catalyzed by thrombin appears dependent upon interactions with both anion-binding exosites I and II, and converts the heterodimer to the active cofactor, factor VIIIa. This protein, comprised of A1, A2, and A3-C1-C2 subunits, is labile due to weak affinity of the A2 subunit. Association of factor VIIIa with factor IXa to form the intrinsic factor Xase complex is membrane-dependent and involves multiple inter-protein contacts that remain poorly characterized. This complex catalyzes the conversion of factor X to factor Xa, a reaction that is essential for the propagation phase of coagulation. The role of factor VIIIa in this complex is to increase the catalytic efficiency for factor Xa generation by several orders of magnitude. Mechanisms for the down-regulation of factor Xase focus upon inactivation of the cofactor and include dissociation of the A2 subunit as well as activated protein C-catalyzed proteolysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513527     DOI: 10.1532/IJH97.05113

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  58 in total

1.  Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa.

Authors:  Keiji Nogami; Hironao Wakabayashi; Kyla Schmidt; Philip J Fay
Journal:  J Biol Chem       Date:  2002-11-07       Impact factor: 5.157

2.  Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop.

Authors:  Katrin Sichler; Erhard Kopetzki; Robert Huber; Wolfram Bode; Karl-Peter Hopfner; Hans Brandstetter
Journal:  J Biol Chem       Date:  2002-11-19       Impact factor: 5.157

3.  Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.

Authors:  P Vincent Jenkins; Julie L Dill; Qian Zhou; Philip J Fay
Journal:  Biochemistry       Date:  2004-05-04       Impact factor: 3.162

4.  Localization of a pH-dependent, A2 subunit-interactive surface within the factor VIIIa A1 subunit.

Authors:  Keiji Nogami; Hironao Wakabayashi; Charles Ansong; Philip J Fay
Journal:  Biochim Biophys Acta       Date:  2004-09-01

5.  Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers.

Authors:  S S Stoylova; P J Lenting; G Kemball-Cook; A Holzenburg
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

6.  Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.

Authors:  L Tagliavacca; N Moon; W R Dunham; R J Kaufman
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

7.  X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

Authors:  H Brandstetter; M Bauer; R Huber; P Lollar; W Bode
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

8.  Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site.

Authors:  P J Fay; T Beattie; C F Huggins; L M Regan
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

Review 9.  Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.

Authors:  E L Saenko; M Shima; A G Sarafanov
Journal:  Trends Cardiovasc Med       Date:  1999-10       Impact factor: 6.677

10.  A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.

Authors:  S Pemberton; P Lindley; V Zaitsev; G Card; E G Tuddenham; G Kemball-Cook
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

View more
  26 in total

1.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

2.  Mapping the binding region on the low density lipoprotein receptor for blood coagulation factor VIII.

Authors:  James H Kurasawa; Svetlana A Shestopal; Elena Karnaukhova; Evi B Struble; Timothy K Lee; Andrey G Sarafanov
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

3.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 4.  Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity.

Authors:  Dudley K Strickland; Dianaly T Au; Patricia Cunfer; Selen C Muratoglu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-06       Impact factor: 8.311

5.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

6.  Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.

Authors:  Daniel J D Johnson; Jonathan Langdown; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

Review 7.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

8.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

Review 9.  Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.

Authors:  John Puetz
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

10.  Helical organization of blood coagulation factor VIII on lipid nanotubes.

Authors:  Jaimy Miller; Daniela Dalm; Alexey Y Koyfman; Kirill Grushin; Svetla Stoilova-McPhie
Journal:  J Vis Exp       Date:  2014-06-03       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.